Alzheimer's disease begins with a long period during which abnormal amyloid and tau proteins build up in the brain without ...

The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

Targeting toxic oligomers without binding to plaque, designed to reduce the risk of ARIA and potentially deliver enhanced ...

For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...

Dec. 19, 2024 — Researchers have discovered a surprising link between a chronic gut infection caused by a common virus and the development of Alzheimer's disease in a subset of people.

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according to a report. The report by GlobalData, a data and analytics company, showed ...

Melatonin is a supplement most often taken as a sleep aid. Some research shows it may have benefits for people with Alzheimer’s disease, but current evidence is mixed. Melatonin is a hormone ...

Jan. 8, 2025 — Declining blood levels of two molecules that occur naturally in the body track closely with worsening Alzheimer's disease, particularly in women. Levels were found to drop ...

Amyloid-related imaging abnormalities are the most impactful adverse effect of anti-amyloid-β immunotherapies. Here, the authors review the detection, underlying mechanisms and clinical ...

Due, in part, to the logical nature of the approach, combination therapy is already widely used in clinical practice. Although compounds with a combined cholinergic–glutamatergic action have ...

Mild traumatic brain injury leads to reactivation of herpes simplex virus type 1, which may promote neurodegeneration and contribute to Alzheimer’s, new research suggested.